VRTX

Vertex Pharmaceuticals

October 13, 2026 · market open

Rarity

1.29

Peak move

−4.25%

Float cap

$128.4B

Vertex Pharmaceuticals is a Boston-based global biotechnology company that discovers, develops, and commercializes medicines for serious diseases, with a focus on specialty markets. Its approved therapies treat cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and acromegaly, sold to patients, hospitals, and health systems worldwide. It also funds research in kidney disease, type 1 diabetes, and neuropathic pain.

• analyst_ratingOct 13

  TD Cowen reiterated a Buy rating on Vertex Pharmaceuticals on October 13, 2026.

  Webmarketbeat.com
• Key eventanalyst_ratingOct 12

  BofA Securities lowered its price target on Vertex Pharmaceuticals to $667 from $672 while keeping a Buy rating, updating estimates ahead of Q3 and projecting Trikafta revenue of $2.42B, Alyftrek $688M, Casgevy $83M and Journavx $68M.

  Webtipranks.comWebes.investing.com
• Key eventanalyst_ratingOct 12

  UBS raised its price target on Vertex Pharmaceuticals to $615 from $585 and kept a Buy rating.

  Webstockanalysis.comWebtipranks.com
• Key eventanalyst_ratingOct 12

  BMO Capital maintained a Buy rating and $600 price target on Vertex Pharmaceuticals.

  Webstockanalysis.com
• clinical_readoutOct 9

  Vertex presented interim ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) data at the North American Cystic Fibrosis Conference showing recovery of exocrine pancreatic function in children aged 2-5, with 48 in a PERT discontinuation substudy able to stop pancreatic enzyme therapy.

  Webvermoegenszentrum.chWebinvestors.vrtx.com
• analyst_ratingOct 7 · 10:26 ET

  Morgan Stanley analyst Terence Flynn assigned a Buy rating to Vertex Pharmaceuticals with a $665.00 price target.

  Webmarkets.businessinsider.com